CION Ameerpet
A WHO grade (1 to 4) tells you a lot about a brain tumour — but it is not the whole story. We explain what grade means for prognosis, honestly and clearly, so your family can plan with confidence.
If you or someone you love has just been told a brain tumour has a "grade", the next question is almost always the same: what does this mean for the future? It is a fair, human question — and you deserve a clear, honest answer.
Brain tumours are not described using the Stage 1 to Stage 4 system most people know. Instead, the World Health Organization (WHO) gives them a grade from 1 to 4, based on how the tumour cells look under a microscope. A higher grade means the cells look more abnormal and tend to grow faster. The grade is the single biggest factor in prognosis — but, as you will see, it is only part of the picture. For the full picture of what each level means, see our companion guide to WHO brain tumour grades (1–4) explained.
Brain tumours are graded, not staged. Most cancers use the TNM stage system, which describes how far a tumour has spread. Brain tumours almost never spread outside the central nervous system, so the WHO uses a grade (1–4) that reflects how aggressive the cells appear instead. The 2021 WHO classification (endorsed by EANO) also folds in molecular markers such as IDH — which is why grade alone no longer tells the whole story.
The table below is a general guide for adults. These are broad patterns, not promises — the markers and personal factors covered further down can shift the outlook in either direction within any grade. Always discuss your exact diagnosis with your oncologist.
| WHO Grade | How it behaves | Common examples | General outlook |
|---|---|---|---|
| Grade 1 | Very slow growing; well-defined edges | Pilocytic astrocytoma, many meningiomas | Often controlled long-term; surgery alone can be enough for some |
| Grade 2 | Slow growing; can change over years | Diffuse astrocytoma, oligodendroglioma | Frequently good; many people live well for years with follow-up |
| Grade 3 | More aggressive; infiltrates tissue | Anaplastic astrocytoma, anaplastic oligodendroglioma | Variable; depends heavily on molecular markers and surgery |
| Grade 4 | Fast growing; the most aggressive | Glioblastoma (GBM) | Shortest median survival, but ranges are wide and improving |
Pattern descriptions adapted from NCCN and EANO guidance on central nervous system tumours. "Outlook" reflects general published trends, not an individual prediction.
Want the type-by-type numbers behind these patterns? See our detailed page on brain tumour survival rates by type & grade.
Here is the part that matters most for families: two people with the same grade can have very different journeys. Grade describes how the cells look, but several other factors shape the real outlook. At CION, we look at all of them together — because a number on a pathology report is never the full answer.
IDH mutation, MGMT methylation and 1p/19q co-deletion can dramatically change the outlook within the same grade. An IDH-mutant tumour generally behaves more favourably than an IDH wild-type tumour of the same grade.
Younger age and being able to manage daily activities well are consistently linked to a better outlook across grades.
How much tumour can be safely removed at surgery — coordinated with accredited neurosurgical partners — is one of the strongest factors we can influence.
Where the tumour sits and its exact histological type affect both treatment options and the expected course.
This is exactly why CION reviews every case at a multidisciplinary tumour board before any plan is finalised. If you already have an MRI and biopsy report, share it with our team for a free written second opinion — or explore brain tumour treatment in Hyderabad.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Numbers on a report are not a destiny. Our neuro-oncology team will walk through your grade, your molecular markers, and what they realistically mean — with you, not at you.
Prognosis is not read off the grade alone. Your CION team builds a realistic picture from several pieces of information — the steps below show how that comes together.
For gliomas in particular, three markers do much of the heavy lifting in prognosis. They are tested on the tumour tissue, not the scan.
IDH (isocitrate dehydrogenase) status is one of the most powerful prognostic markers in glioma. IDH-mutant tumours generally grow more slowly and carry a more favourable outlook than IDH wild-type tumours of the same grade. The 2021 WHO classification (supported by EANO) is built around this marker.
MGMT is a DNA-repair gene. When it is "methylated" (switched off), a high-grade tumour tends to respond better to alkylating chemotherapy given alongside radiation. For grade 4 glioblastoma, a methylated MGMT marker is linked to a longer median survival than an unmethylated one — which is why this test should be part of the standard workup.
The loss of parts of chromosomes 1p and 19q together defines oligodendroglioma and is associated with a more favourable outlook and a better response to combined chemotherapy and radiation.
An older grade 3 tumour with an IDH mutation can carry a better outlook than a grade 3 tumour without it — sometimes a markedly better one. This is why EANO and NCCN guidelines now classify many gliomas by their molecular markers, not by grade alone. If your biopsy report does not mention IDH, MGMT or 1p/19q, it is worth asking whether these tests were done.
Families searching for the outlook of a high-grade brain tumour deserve straight answers without false hope or false despair. For glioblastoma, the most common grade 4 brain tumour, published data report a median overall survival of roughly 12 to 18 months with standard treatment (surgery, then combined chemotherapy and radiation). Around 5 to 10% of patients are alive at 5 years in many large series (NCCN, EANO).
It is important to understand what these numbers are — and are not:
We share these ranges so you can plan practically — never as a guarantee in either direction. The things that can be influenced — getting the right diagnosis, completing the right treatment, and protecting quality of life — are where we focus together. To understand how a grade 4 tumour is treated, see brain tumour treatment in Hyderabad.
Prognosis is not a single moment — it is something your team watches over time. After treatment, follow-up MRI scans are scheduled to check on the tumour.
If recurrence is confirmed, the tumour board discusses options — further surgery (coordinated with accredited neurosurgical partners), repeat radiation, systemic therapy, or a clinical trial. The plan is always tailored to the tumour and to what matters to you.
For brain tumours, a second opinion is most valuable in a few specific situations — and seeking one is a normal, sensible part of navigating a serious diagnosis. You deserve to feel confident in the plan.
CION offers a dedicated, free written second-opinion service across our Hyderabad centres and 35+ centres beyond, with same-week appointments. Start with the brain cancer & tumour hub, or request a callback now and bring your reports along.
Get a free written second opinion from CION's neuro-oncology tumour board — especially valuable if molecular testing (IDH, MGMT) has not yet been arranged on the tissue.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.The WHO grade (1 to 4) is the single biggest factor in prognosis. Grade 1 tumours grow very slowly and are often controlled for many years — sometimes with surgery alone. Grade 2 tumours grow slowly but can change over time. Grade 3 tumours are more aggressive and usually need surgery, radiation and chemotherapy. Grade 4 tumours, such as glioblastoma, are the most aggressive. But grade is not the whole story — age, how much tumour was safely removed, your day-to-day function, and molecular markers like IDH and MGMT all shape the outlook. Two people with the same grade can have very different journeys.
For glioblastoma (the most common grade 4 brain tumour), published data report a median overall survival of roughly 12 to 18 months with standard treatment — surgery, then combined chemotherapy and radiation. Some people live considerably longer; around 5 to 10% are alive at 5 years in many series (NCCN, EANO). "Median" means half do better and half do worse — it is not a deadline for any one person. Younger age, more complete safe removal, good functional status, and a methylated MGMT marker all point to a better outlook. We share these ranges honestly so you can plan, never as a fixed number.
Yes. Some grade 2 tumours can change ("transform") into a higher grade over months or years — this is one reason regular MRI follow-up matters even when a tumour is behaving calmly. Transformation is not certain and the speed varies a lot between tumour types. Molecular markers help predict the risk: for example, IDH-mutant tumours generally transform more slowly than IDH wild-type tumours. If a follow-up scan or new symptoms suggest a change, your CION tumour board re-evaluates the plan — often with a repeat biopsy — before any decision is made.
Grade describes how the tumour cells look under a microscope, but it is only one ingredient. Outcomes also depend on your age, your functional status (how well you manage daily activities), how much tumour was safely removed at surgery, the tumour's exact location, and its molecular markers — IDH mutation, MGMT methylation, and 1p/19q co-deletion. A grade 3 tumour that is IDH-mutant and was largely removed can carry a far better outlook than a grade 3 tumour that is IDH wild-type. This is why CION reviews the full molecular and clinical picture, not the grade alone.
Median survival is the time at which half of patients in a study are still living and half are not. It is a useful planning figure for a group, but it cannot predict what will happen to one individual. Many people live well beyond the median; some less. Survival figures also come from older studies and may not reflect the newest treatments or your specific molecular profile. We encourage families to use these numbers for practical planning while focusing on the things that can be influenced — completing the right treatment, managing symptoms, and maintaining quality of life. Ask your CION oncologist what the data mean for your exact diagnosis.
High-grade tumours do need timely treatment, but "timely" is not the same as "rushed". The most important early steps are getting the right diagnosis — including molecular testing on the tissue — and having the case reviewed by a multidisciplinary tumour board so the plan fits the exact tumour. Skipping these steps to start faster can lead to the wrong treatment. CION offers same-week appointments and a free written second opinion so families can move quickly and confidently. If you already have an MRI and biopsy report, share it with us for a prompt review.
After treatment, follow-up MRI scans are scheduled — often every 2 to 3 months at first for high-grade tumours, then spaced further apart if things are stable. Scans are read carefully because post-treatment inflammation ("pseudoprogression") can mimic regrowth, especially in the first few months after chemoradiation. Experienced neuro-oncologists factor this in before changing any plan. New or worsening symptoms — such as fresh headaches, seizures, or weakness — are also reviewed promptly. If recurrence is confirmed, options including further surgery (coordinated with neurosurgical partners), repeat radiation, systemic therapy, or a clinical trial are discussed by the tumour board.
Browse our complete guide to brain tumours and brain cancer — symptoms, scans, tumour types, treatment, prognosis and life after treatment. Tap any topic to read more.